Alectinib

Drug Profile

Alectinib

Alternative Names: AF-802; Alecensa; ALECENSARO; Alectinib hydrochloride; CH-5424802; RG-7853; RO-5424802; RO-5452802

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Chugai Pharmaceutical
  • Developer Chugai Pharmaceutical; Roche
  • Class Antineoplastics; Carbazoles; Morpholines; Nitriles; Phenyl ethers; Piperidines; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer

Most Recent Events

  • 27 Feb 2017 Registered for Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater) in Taiwan (PO)
  • 27 Feb 2017 Efficacy data from the phase I/II NP28761 and NP28673 trials in Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater) released by Chugai Pharmaceutical
  • 21 Feb 2017 Registered for Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater) in European Union, Norway, Liechtenstein, Iceland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top